Closed
The Marked Chart Wire · Business
CRISPR Therapeutics
CRISPR Therapeutics reported $99 million in CASGEVY product sales for the third quarter and received FDA designations for CTX310. The company posted a $111.4 million net loss and holds $2.277 billion in cash.
Prices from Based on Mon, Nov 2 close · Opens Tue 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
HotApple
Shares fell after the company projected 7% to 10% sales expansion for the December quarter, even though fourth-quarter revenue climbed 12% to $114.5 billion. China figures also came in below estimates.
Apple
Apple's chief financial officer stated that the company anticipates continued increases in the cost of memory components.
Apple
Apple's CFO projects a gross margin of 45 to 46 percent for the first fiscal quarter, citing memory chip and AI costs. The company also expects services revenue to rise 8 to 9 percent and reported buying back $24 billion in shares last quarter.
Apple
Analysts estimate Apple's first quarter revenue will increase between 7 and 10 percent, compared to a consensus forecast of 6.1 percent growth.
HotGrab
Grab reported third-quarter revenue of $1.112 billion and adjusted EBITDA of $237 million. The company lifted its full-year 2026 revenue guidance to $4.15 billion to $4.20 billion and adjusted EBITDA to $790 million to $800 million.
Alphabet
Alphabet has filed to issue up to €6 billion in notes across seven separate tranches.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.